 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...1011121314151617181920...208209» |
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
Journal: Remimazolam tosylate versus propofol for postoperative delirium in frail elderly patients undergoing hip surgery. (Pubmed Central) - Feb 2, 2026
No abstract available
- || remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
Journal, Adverse events: Adverse event prediction in propofol-remimazolam tosilate anesthesia. (Pubmed Central) - Feb 2, 2026
The RF model, developed using key perioperative indicators, effectively predicts the risk of ARAEs during propofol-remimazolam tosilate anesthesia. Surgical duration, hemodynamic stability, and respiratory recovery status are the most significant predictors.
- ||| AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Clinical, P3 data, Retrospective data, Journal: Impact of treatment interruption on the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: a post-hoc analysis of a phase 3 trial. (Pubmed Central) - Feb 2, 2026
P3
The incidence of overall adverse events was similar between the two groups. Interrupted vunakizumab treatment reduced the clinical response and quality of life in patients with moderate-to-severe plaque psoriasis.
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Review, Journal: Hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors. (Pubmed Central) - Feb 2, 2026
Safety profile showed good tolerability of hetrombopag (monotherapy or combined with rhTPO/rhIL-11) in patients. Hetrombopag may be an effective and well-tolerated treatment option for CIT in patients with solid tumors.
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Perjeta (pertuzumab) / Roche
New trial: Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC (clinicaltrials.gov) - Feb 1, 2026
P=N/A, N=60, Not yet recruiting, Sponsor: The First Affiliated Hospital of Guangzhou Medical University
- |||| Irene (pyrotinib) / Jiangsu Hengrui Pharma
Enrollment closed: Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer (clinicaltrials.gov) - Feb 1, 2026
P3, N=160, Active, not recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hetrombopag may be an effective and well-tolerated treatment option for CIT in patients with solid tumors. Recruiting --> Active, not recruiting
- | Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma, gliclazide / Generic mfg.
Journal: Henagliflozin enhances frontal neural activation and cognitive function versus gliclazide in type 2 diabetes patients with mild cognitive impairment: A 16-week randomized controlled trial. (Pubmed Central) - Jan 31, 2026
Recruiting --> Active, not recruiting No abstract available
- | lapatinib / Generic mfg., Irene (pyrotinib) / Jiangsu Hengrui Pharma
Clinical, Retrospective data, Review, Journal: Radiation therapy combined with tyrosine kinase inhibitors in 826 patients with HER2-positive breast cancer brain metastases: a systematic review and network meta-analysis. (Pubmed Central) - Jan 31, 2026
No abstract available Bayesian network meta-analysis (NMA) was conducted to integrate direct and indirect comparisons, addressing the lack of head-to-head trials.
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Synergistic Anticancer Effects of Apatinib and PD-L1 Inhibition in Breast Cancer. (Pubmed Central) - Jan 31, 2026
In addition, the levels of p-ERK, NF-?B, and Slug were markedly reduced in vitro. Collectively, these findings support the potential clinical utility of combining apatinib and PD-L1 inhibition, as evidenced by consistent in vitro and in vivo synergy.
- | TheraCIM (nimotuzumab) / Daiichi Sankyo, Biocon, Biotech Pharma, HRS-4642 / Jiangsu Hengrui Pharma
Enrollment change: HRS-4642 combined with Nimotuzumab in the treatment of recurrent or metastatic pancreatic ductal adenocarcinoma with KRAS G12D mutation that has failed systemic therapy (EUDRACT) - Jan 31, 2026
P1/2, N=20, Recruiting, Sponsor: West China Hospital,Sichuan University; West China Hospital,Sichuan University
Collectively, these findings support the potential clinical utility of combining apatinib and PD-L1 inhibition, as evidenced by consistent in vitro and in vivo synergy. N=10 --> 20
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New trial: A multicenter, prospective, phase II clinical study of hytrombopag ethanolamine tablets combined with immunosuppressive therapy in newly diagnosed patients with non-severe aplastic anemia (EUDRACT) - Jan 31, 2026
P=N/A, N=76, Not yet recruiting, Sponsor: Tianjin Medical University General Hospital; Tianjin Medical University General Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New trial: A Single-Arm, Exploratory Clinical Study of Irinotecan Liposome (II) in Combination with Adebrelimab for Platinum-Resistant Recurrent Ovarian Cancer (EUDRACT) - Jan 31, 2026
P=N/A, N=35, Not yet recruiting, Sponsor: Renji Hospital Shanghai Jiao Tong University School of Medicine; Renji Hospital Shanghai Jiao Tong University School of Medicine
- | Olinvyk (oliceridine) / Trevena, AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: A study on the efficacy of Tegileridine and Oliceridine for patient-controlled analgesia after urological laparoscopic surgery in elderly patients (EUDRACT) - Jan 31, 2026
P=N/A, N=168, Not yet recruiting, Sponsor: Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital); Central Hospital of Dalian University of Technology (Dalian M
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New trial: Pharmacodynamic Analysis of Intravenous Remimazolam Tosylate for Sedation in Obese Patients: A Prospective, Double-Blind, Single-Center, Randomized Clinical Trial (EUDRACT) - Jan 31, 2026
P=N/A, N=110, Not yet recruiting, Sponsor: The First Affiliated Hospital, Sun Yat-sen University; The First Affiliated Hospital, Sun Yat-sen University
- | AiTan (rivoceranib) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial: A Study of Apatinib + Lenvatinib Conversion Followed by Surgical Resection for Unresectable Advanced HCC: A Prospective, Single-Arm, Historical Control, IIT Study (EUDRACT) - Jan 31, 2026
P=N/A, N=73, Not yet recruiting, Sponsor: Affiliated hangzhou first people's hospital, zhejiang university school of medicine; Affiliated hangzhou first people's hospital, zhejiang university
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: The Effect of Postoperative Analgesia with Tegileridine Fumarate on Quality of Recovery in Patients Undergoing Colorectal Cancer Surgery: A Randomized, Double-Blind, Active-Controlled Clinical Study (EUDRACT) - Jan 31, 2026
P=N/A, N=96, Not yet recruiting, Sponsor: The First Affiliated Hospital of the University of South China; The First Affiliated Hospital of the University of South China
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New trial: Effect Of Remimazolam Tosylate Versus Propofol On Postoperative Delirium In Preoperatively Frail Elderly Patients Undergoing Hip Surgery: A Multicenter Randomised Controlled Trial (EUDRACT) - Jan 31, 2026
P=N/A, N=800, Not yet recruiting, Sponsor: zhongda hospital southeast university; zhongda hospital southeast university
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: Exploratory Study on the Efficacy of Tegileridine Combined with Butorphanol in Managing Moderate to Severe Postoperative Pain in Gynecological Laparoscopic Surgery Patients (EUDRACT) - Jan 31, 2026
P=N/A, N=80, Not yet recruiting, Sponsor: Chinese People's Liberation Army Northern Theater Command General Hospital; Chinese People's Liberation Army Northern Theater Command General Hospital
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New trial: Efficacy and safety of doxorubicin liposomal and adebrelimab in the treatment of osteosarcoma failed standard treatment: a multicenter, interventional clinical study (EUDRACT) - Jan 31, 2026
P=N/A, N=67, Not yet recruiting, Sponsor: Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Clinical study of Carrilizumab combined with Apatinib in prevention of postoperative recurrence of early hepatocellular carcinoma (EUDRACT) - Jan 31, 2026
P=N/A, N=55, Not yet recruiting, Sponsor: Medical Institution; Medical Institution
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: The Efficacy and Safety of Tegileridine in Moderate to Severe Pain Management Following General Anesthesia in Elderly Total Hip Replacement Patients (EUDRACT) - Jan 31, 2026
P=N/A, N=182, Recruiting, Sponsor: Huaihe Hospital of Henan University; Huaihe Hospital of Henan University
- | Olinvyk (oliceridine) / Trevena, Sufenta (sufentanil) / Akorn, AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: A Comparison of the Efficacy of Novel G-Protein Biased (EUDRACT) - Jan 31, 2026
P=N/A, N=180, Not yet recruiting, Sponsor: Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital); Central Hospital of Dalian University of Technology (Dalian M
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: Tegileridine Pretreatment for the Prevention of Fentanil-Induced Cough During Anesthesia Induction: A Clinical Study (EUDRACT) - Jan 31, 2026
P=N/A, N=210, Not yet recruiting, Sponsor: Weifang People's Hospital; Weifang People's Hospital
- | Sufenta (sufentanil) / Akorn, remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New trial: Clinical Application Research on the Early Recovery Quality of Patients Undergoing Daytime Laparoscopic Cholecystectomy with Opioid-Free Anesthesia Protocol (EUDRACT) - Jan 31, 2026
P=N/A, N=118, Not yet recruiting, Sponsor: General Hospital of Western Theater Command of PLA; General Hospital of Western Theater Command of PLA
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: Research on the Application of Tegileridine for Postoperative Analgesia in Elderly Patients after Total Knee Arthroplasty (EUDRACT) - Jan 31, 2026
P=N/A, N=120, Not yet recruiting, Sponsor: Lu'an Hospital of Anhui Medical University; Lu'an Hospital of Anhui Medical University
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: Exploring the Safety and Efficacy of Tegileridine for Postoperative Analgesia in Elderly Patients Undergoing Hip Arthroplasty (EUDRACT) - Jan 31, 2026
P=N/A, N=226, Not yet recruiting, Sponsor: The First Affiliated Hospital of University of Science and Technology of China; The First Affiliated Hospital of University of Science and Technology
- | Sufenta (sufentanil) / Akorn, AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: Tegileridine Pretreatment for the Prevention of Sufentanil-Induced Cough During Anesthesia Induction: A Clinical Study (EUDRACT) - Jan 31, 2026
P=N/A, N=204, Completed, Sponsor: Yan
- | Sufenta (sufentanil) / Akorn, AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: The efficacy and safety of Tegileridine versus sufentanil for postoperative analgesia after laparoscopic colorectal cancer surgery - a multicenter, randomized controlled, non-inferiority study (EUDRACT) - Jan 31, 2026
P=N/A, N=488, Not yet recruiting, Sponsor: Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Neoadjuvant FOLFOXIRI chemotherapy with or without camrelizumab in the treatment of locally advanced rectal cancer: a retrospective cohort study (EUDRACT) - Jan 31, 2026
P=N/A, N=150, Not yet recruiting, Sponsor: Harbin medical university cancer hospital; Harbin medical university cancer hospital
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New trial: Effects of Retagliptin Phosphate on BMD and bone metabolism markers in elderly female patients with type 2 diabetes mellitus (EUDRACT) - Jan 31, 2026
P=N/A, N=86, Not yet recruiting, Sponsor: The Fifth Affiliated Hospital of Sun Yat-sen University; The Fifth Affiliated Hospital of Sun Yat-sen University
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: A national multicenter, real-world study evaluating the safety and efficacy of tegileridine fumarate injection in the treatment of postoperative pain (EUDRACT) - Jan 31, 2026
P=N/A, N=1000, Not yet recruiting, Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: Efficacy and safety of tegileridine for postoperative analgesia in patients undergoing thoracoscopic lung resection (EUDRACT) - Jan 31, 2026
P=N/A, N=144, Not yet recruiting, Sponsor: Nanjing Drum Tower Hospital Group Suqian Hospital; Nanjing Drum Tower Hospital Group Suqian Hospital
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: Effect of tegileridine fumarate injection on gastrointestinal function recovery after laparoscopic myomectomy: a single-center, randomized, double-blind, positive controlled study (EUDRACT) - Jan 31, 2026
P=N/A, N=120, Not yet recruiting, Sponsor: Chengdu Second People
- | Sufenta (sufentanil) / Akorn, remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New trial: Prospective Clinical Study on the Use of Fumaric Acid Tigelidine for the Prevention of Nausea and Vomiting Following Gynecological Laparoscopic Surgery (EUDRACT) - Jan 31, 2026
P=N/A, N=118, Not yet recruiting, Sponsor: Henan Univ,Huaihe Hosp; Henan Univ,Huaihe Hosp
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New trial: A single-arm, multicenter, prospective clinical study on neoadjuvant therapy of elderly patients with advanced esophageal squamous cell carcinoma using adebrelimab combined with albumin-paclitaxel (EUDRACT) - Jan 31, 2026
P=N/A, N=31, Not yet recruiting, Sponsor: Fujian Medical University First Affiliated Hospital; Fujian Medical University First Affiliated Hospital
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: A Non-Inferiority Randomized Controlled Trial of Tegileridine for Postoperative Analgesia After Laparoscopic Cholecystectomy (EUDRACT) - Jan 31, 2026
P=N/A, N=120, Not yet recruiting, Sponsor: Suzhou Ninth People's Hospital; Suzhou Ninth People's Hospital
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: The Effect of Tegileridine Fumarate Injection on Gastrointestinal Function After Laparoscopic Surgery:A Randomized Controlled Study (EUDRACT) - Jan 31, 2026
P=N/A, N=46, Not yet recruiting, Sponsor: The Affiated Cancer Hospital of Guizhou Medical University; The Affiated Cancer Hospital of Guizhou Medical University
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New trial: Trastuzumab rezetecan alone or in combination with adebrelimab in advanced solid tumors with HER2 expression or mutation: a prospective, multicenter, open, nonrandomized, multicohort study. (EUDRACT) - Jan 31, 2026
P=N/A, N=200, Not yet recruiting, Sponsor: The Affiliated Hospital of Xuzhou Medical University; The Affiliated Hospital of Xuzhou Medical University
- | AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
New trial: An open,non randomized, multicenter clinical studies of rezvilutamide or standard androgen deprivation therapy as adjuvant therapy in prostate cancer patients with poor PSA control after radical prostatectomy (EUDRACT) - Jan 31, 2026
P=N/A, N=50, Not yet recruiting, Sponsor: The First Bethune Hospital of Jilin University; The First Bethune Hospital of Jilin University
- | Sufenta (sufentanil) / Akorn, AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: A Comparative Study of Tegileridine Fumarate versus Sufentanil for Postoperative Analgesia Following Laparoscopic Total Hysterectomy: A Prospective, Randomized, Double-Blind, Controlled Clinical Trial Focusing on Quality of Recovery as the Primary Endpoint. (EUDRACT) - Jan 31, 2026
P=N/A, N=120, Not yet recruiting, Sponsor: Liaocheng Second People's Hospital; Liaocheng Second People's Hospital
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
New trial: Exploration of Targeted Therapy Regimens for Triple-Positive Breast CancerExploration of Targeted Therapy Regimens for Triple-Positive Breast Cancer (EUDRACT) - Jan 31, 2026
P=N/A, N=200, Not yet recruiting, Sponsor: The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University
- | AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial: Hepatic Arterial Infusion Chemotherapy Combined with Camrelizumab and Lenvatinib for Advanced Hepatocellular Carcinoma: A Single-Center Retrospective Study (EUDRACT) - Jan 31, 2026
P=N/A, N=64, Not yet recruiting, Sponsor: Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New trial: An Exploratory Clinical Study of Adebrelimab Combined with Apatinib and Chemotherapy as Neoadjuvant Therapy for Initially Unresectable Stage III Non-Small Cell Lung Cancer (EUDRACT) - Jan 31, 2026
P=N/A, N=52, Not yet recruiting, Sponsor: Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital
- | Sufenta (sufentanil) / Akorn, AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: Comparison of Tegileridine and Sufentanil for Multimodal Analgesia in Gynecological Laparoscopic Surgery: A Randomized Double-blinded Controlled Trial (EUDRACT) - Jan 31, 2026
P=N/A, N=168, Not yet recruiting, Sponsor: Obstetrics and Gynecology Hospital, Fudan University; Obstetrics & Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and D
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: The application effect of tegileridine in inhibiting laryngeal mask airway insertion response in elderly patients undergoing urological surgery (EUDRACT) - Jan 31, 2026
P=N/A, N=92, Not yet recruiting, Sponsor: The First People
- | Sufenta (sufentanil) / Akorn, remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New trial: Effect of Remimazolam on Postoperative Patient-Reported Outcomes in Frail Elderly Patients Undergoing Spinal Surgery (EUDRACT) - Jan 31, 2026
P=N/A, N=126, Not yet recruiting, Sponsor: The Second Hospital of Shanxi Medical University; The Second Hospital of Shanxi Medical University
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: Establishing the Median and 95% Effective Doses of Tegileridine for Immediate Post-Surgical Analgesia Following Totally Extraperitoneal Hernioplasty: A Sequential Dose-Finding Study (EUDRACT) - Jan 31, 2026
P=N/A, N=40, Not yet recruiting, Sponsor: Central Hospital of Dalian University of Technology; Central Hospital of Dalian University of Technology
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Neoadjuvant TACE Combined with Camrelizumab and Apatinib for Centrally Located Hepatocellular Carcinoma(NEO-CENTACT): A Single-Arm, Prospective, Exploratory Study (EUDRACT) - Jan 31, 2026
P=N/A, N=40, Not yet recruiting, Sponsor: West China Hospital, Sichuan University; Sichuan University West China Hospital
- | cordycepin (OVI-123) / OncoVista
New trial: Clinical Study on the Application of Cordycepin in Combination with Anti-PD-1 for the Treatment of Non-Small Cell Lung Cancer (EUDRACT) - Jan 31, 2026
P=N/A, N=9, Completed, Sponsor: Changzhou No.2 People
- | Sufenta (sufentanil) / Akorn, AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: Comparison of postoperative Analgesia given Sufentanil or Tegileridine in Laparoscopic Appendectomy, a prospective, randomized, controlled, blinded study (EUDRACT) - Jan 31, 2026
P=N/A, N=150, Not yet recruiting, Sponsor: Puyang Oil Field General Hospital; Puyang Oil Field General Hospital